Literature DB >> 15793102

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Scott T Micek1, Ann E Lloyd, David J Ritchie, Richard M Reichley, Victoria J Fraser, Marin H Kollef.   

Abstract

Pseudomonas aeruginosa bloodstream infection is a serious infection with significant patient mortality and health-care costs. Nevertheless, the relationship between initial appropriate antimicrobial treatment and clinical outcomes is not well established. This study was a retrospective cohort analysis employing automated patient medical records and the pharmacy database at Barnes-Jewish Hospital. Three hundred five patients with P. aeruginosa bloodstream infection were identified over a 6-year period (January 1997 through December 2002). Sixty-four (21.0%) patients died during hospitalization. Hospital mortality was statistically greater for patients receiving inappropriate initial antimicrobial treatment (n = 75) compared to appropriate initial treatment (n = 230) (30.7% versus 17.8%; P = 0.018). Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment (adjusted odds ratio [AOR], 2.04; 95% confidence interval [CI], 1.42 to 2.92; P = 0.048), respiratory failure (AOR, 5.18; 95% CI, 3.30 to 8.13; P < 0.001), and circulatory shock (AOR, 4.00; 95% CI, 2.71 to 5.91; P < 0.001) as independent determinants of hospital mortality. Appropriate initial antimicrobial treatment was administered statistically more often among patients receiving empirical combination antimicrobial treatment for gram-negative bacteria compared to empirical monotherapy (79.4% versus 65.5%; P = 0.011). Inappropriate initial empirical antimicrobial treatment is associated with greater hospital mortality among patients with P. aeruginosa bloodstream infection. Inappropriate antimicrobial treatment of P. aeruginosa bloodstream infections may be minimized by increased use of combination antimicrobial treatment until susceptibility results become known.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793102      PMCID: PMC1068618          DOI: 10.1128/AAC.49.4.1306-1311.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.

Authors:  E B El Amari; E Chamot; R Auckenthaler; J C Pechère; C Van Delden
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

2.  Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care.

Authors:  Stephan Harbarth; Karin Ferrière; Stéphane Hugonnet; Bara Ricou; Peter Suter; Didier Pittet
Journal:  Arch Surg       Date:  2002-12

3.  Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.

Authors:  G Grisaru-Soen; L Lerner-Geva; N Keller; H Berger; J H Passwell; A Barzilai
Journal:  Pediatr Infect Dis J       Date:  2000-10       Impact factor: 2.129

4.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.

Authors:  M J Richards; J R Edwards; D H Culver; R P Gaynes
Journal:  Crit Care Med       Date:  1999-05       Impact factor: 7.598

5.  Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.

Authors:  E H Ibrahim; S Ward; G Sherman; R Schaiff; V J Fraser; M H Kollef
Journal:  Crit Care Med       Date:  2001-06       Impact factor: 7.598

6.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.

Authors:  E H Ibrahim; G Sherman; S Ward; V J Fraser; M H Kollef
Journal:  Chest       Date:  2000-07       Impact factor: 9.410

Review 7.  Antibiotic resistance in the intensive care unit.

Authors:  M H Kollef; V J Fraser
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

8.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

Authors:  Melinda M Neuhauser; Robert A Weinstein; Robert Rydman; Larry H Danziger; George Karam; John P Quinn
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

Review 9.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.

Authors:  M H Kollef
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

10.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

View more
  150 in total

1.  [Epidemiology of multidrug-resistant organisms in travellers: Results of a 2-year screening in a German level 1 trauma center].

Authors:  J Seifert; M Frank; T Köln; K Beniers; A Kramer; A Ekkernkamp; D Gümbel
Journal:  Unfallchirurg       Date:  2016-03       Impact factor: 1.000

Review 2.  The multiple signaling systems regulating virulence in Pseudomonas aeruginosa.

Authors:  Pol Nadal Jimenez; Gudrun Koch; Jessica A Thompson; Karina B Xavier; Robbert H Cool; Wim J Quax
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

Review 3.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

4.  Impaired pulmonary immunity post-bone marrow transplant.

Authors:  Stephanie M Coomes; Leah L N Hubbard; Bethany B Moore
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

5.  Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.

Authors:  John S Esterly; Jamie Wagner; Milena M McLaughlin; Michael J Postelnick; Chao Qi; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

Review 6.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

7.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

8.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

9.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

10.  ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa: An Update from a Rural Area in Northern India.

Authors:  Aarti Kotwal; Debasis Biswas; Barnali Kakati; Malvika Singh
Journal:  J Clin Diagn Res       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.